达成12亿美元海外授权,押注创新药的老牌石药迎来收获期

国际金融报
19 Feb

近年来,有“魔法子弹”之称的抗体偶联物药物(ADC)在全球医药市场上备受欢迎。其作为精准化疗产品,有望替代现存巨大的化疗药物市场。特别是在2024年,ADC药物的研发迎来爆发期,研发管线和相关交易数量增长迅猛。目前来看,这波热潮仍未冷却。今日(2月19日)盘前,石药集团发布公告宣布,公司附属公司石药集团巨石生物制药有限公司(下称“石药巨石”)与Radiance Biopharma,Inc.(下称“...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10